Inhibitory Effect of Bevacizumab on Corneal Neovascularization and Corneal Conjunctivalization in the Limbal Stem Cell Deficiency Model
Date Issued
2010
Date
2010
Author(s)
Kuo, Kuang-Tzu
Abstract
The cornea locates on the outer structure of optic axis. The transparency of cornea that is angiogenic privilege relies on the regulation among antiangiogenic factors and angiogenic factors and the existence of limbal stem cells between cornea and conjunctiva. If limbal stem cell deficiency (LSCD) develops, corneal neovascularization and conjunctivalization may be manifested following inflammatory cascade, finally leading to decreased corneal transparency and vision. Vascular endothelium growth factor (VEGF) is well-known to play an important role in angiogenesis. The anti-VEGF drug, bevacizumab (Avastin®), which is an anti-cancer medicine was reported to be effective in treating corneal neovascularization in animal experiments and clinical trials recently. In this study, we utilzed a limbal insufficiency rabbit model and treated with different onset time of subconjunctival injection. To compare the inhibitory effect of the early, mid, and late treatment by bevacizumab on corneal pathological changes, the corneal neovascularization and conjunctivalization were grossly recorded and quantified with image analysis, and expression of corneal or conjunctival phenotype by the corneal surface cells was examined immunohistochemically. The most successful group in controlling corneal neovascularization and conjunctivalization was the early treatment group, and followed by the mid and late treatment group sequentially. Although we found that the therapeutic characteristics of bevacizumab was time-dependent, the simulation of real clinical condition such as the experimental model and the therapeutic dosage remains to be investigated in the future.
Subjects
corneal neovascularization
corneal conjunctivalization
limbal stem cell deficiency (LSCD)
bevacizumab
time-dependent
SDGs
Type
thesis
File(s)![Thumbnail Image]()
Loading...
Name
ntu-99-R97643008-1.pdf
Size
23.32 KB
Format
Adobe PDF
Checksum
(MD5):0c8dbcefe23516a938eb4beb9eb7be0a